White Paper

IND Ready Is Not Phase 2 Ready

Download

Download White Paper

The decisions that determine Phase 2 timing are made, or missed, in the first two quarters after the IND opens.

Share

Related Resources

All Resources

FDA CRLs Reveal a Pattern, Syner-G

white-paper

FDA CRLs Reveal a Pattern: Biologic Control Strategy Issues Drive Delays and Rejections

Read More

Researcher wearing protective safety goggles and blue gloves while examining a test tube

post

Building the Future of Breakthrough Therapies Together

Read More

Pharmaceutical lab setting with amber glass bottles and a gloved hand handling vials

post

When the Only Drug Runs Out: Lessons from the Bicillin® L-A Recall

Read More

Understanding the Stakes of IND Submissions, Syner-G

infographic

Understanding the Stakes of IND Submissions: Why Timely Approvals Matter

Read More

Let's move from science to success.